A broad review of next-generation engineered T‑cell technologies outlines advances in receptor engineering, delivery modalities and safety switches designed to extend efficacy against solid tumors. The report catalogs modular CAR architectures, logic-gated receptors and novel payloads that aim to overcome antigen heterogeneity and the immunosuppressive tumor microenvironment. Authors highlight translational challenges—on-target/off-tumor toxicity, persistence, and manufacturing scalability—while noting several candidate approaches are moving into or preparing for clinical trials. The paper serves as a technical roadmap for companies and academic groups prioritizing engineered cellular immunotherapies.